Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Therapie. 2009 Nov-Dec;64(6):365-70. doi: 10.2515/therapie/2009051. Epub 2009 Dec 23.

Second meeting of the French CEIP (Centres d'Evaluation et d'Information sur la Pharmacodépendance). Part II: benzodiazepine withdrawal.

Author information

  • 1CEIP associé, Service de Pharmacologie, CHU Clermont-Ferrand, Clermont-Ferrand, France. authier@hotmail.com

Abstract

The aim of this meeting was to describe the news trends about abuse and addiction of anxiolytics and hypnotics. The part II of this meeting reviewed several aspects of the withdrawing benzodiazepines focusing in particular on clinical symptoms, biological patterns, and strategies for discontinuation. The discontinuation is usually beneficial due to the importance of adverse effects induced by long-term use of benzodiazepines. Several clinicals options have been described including gradual tapering of the current benzodiazepine, substitution with a long acting benzodiazepines or treating the symptoms of withdrawal. Psychological interventions range from a simple support through counselling to expert cognitive-behavioural therapy. However more controlled clinical trials are needed to promote adequate and optimal patient care in management of benzodiazepine withdrawing.

PMID:
20025839
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for EDP Sciences
    Loading ...
    Write to the Help Desk